Search | Page 7 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes.

    ... Outcome of patients with myelodysplastic syndrome after azacitidine failure is poor. In this population, we combined cytarabine ...

    Research Article last updated 07/20/2018 - 5:15pm.

  2. Should elderly patients with higher-risk myelodysplastic syndromes undergo allogeneic hematopoietic stem cell transplantation?

    ... At diagnosis, 86% of MDS patients are ≥60 years. Azacitidine , the only drug that prolongs life in high-risk (HR)-MDS ...

    Research Article last updated 07/20/2018 - 5:15pm.

  3. Prognostic role of immunohistochemical analysis of 5mc in Myelodysplastic Syndromes.

    ... has demonstrated clinical effectiveness; the drugs azacitidine and decitabine have been approved for the treatment of ...

    Research Article last updated 07/20/2018 - 5:15pm.

  4. Myelodysplastic syndromes and autoimmune diseases-Case series and review of literature.

    ... four cases showed improvement in AD after 5- azacitidine treatment. The mechanism(s) of the association between AD and ...

    Research Article last updated 07/20/2018 - 5:15pm.

  5. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update

    ... such as decitabine (5-aza-2'-deoxycytidine) and azacitidine (5-azacytidine), have been approved during the past decade and ...

    Research Article last updated 07/20/2018 - 5:14pm.

  6. Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?

    ... The hypomethylating agents (HMAs) azacitidine and decitabine have changed the treatment landscape of ...

    Research Article last updated 07/20/2018 - 5:14pm.

  7. Combination strategies in myelodysplastic syndromes.

    ... Scoring System . Currently, lenalidomide , azacitidine , and decitabine are the only three FDA-approved drugs ...

    Research Article last updated 07/20/2018 - 5:14pm.

  8. Pharmacotherapy of myelodysplastic syndromes.

    ... the past decade, response to the hypomethylating agents azacitidine and decitabine in non-del(5q) MDS patients remains at ...

    Research Article last updated 07/20/2018 - 5:14pm.

  9. Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes.

    ... agents currently approved in the United States-- azacitidine or decitabine --to patients with aggressive forms of ...

    Research Article last updated 07/20/2018 - 5:14pm.

  10. Myelodysplastic syndromes.

    ... the median survival is 2.5 years. Lenalidomide , azacitidine , and decitabine are all FDA-approved agents to treat ...

    Research Article last updated 07/20/2018 - 5:14pm.